Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial
PaperCitations, authors & open-access status
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 352 citations, 2023 year and hybrid oa status.
352
Citations
2023
Year
hybrid
OA Status